HRP20220406T1 - Pripravci i metode za liječenje raka deplecijom arginina i imunoonkološkim sredstvima - Google Patents
Pripravci i metode za liječenje raka deplecijom arginina i imunoonkološkim sredstvima Download PDFInfo
- Publication number
- HRP20220406T1 HRP20220406T1 HRP20220406TT HRP20220406T HRP20220406T1 HR P20220406 T1 HRP20220406 T1 HR P20220406T1 HR P20220406T T HRP20220406T T HR P20220406TT HR P20220406 T HRP20220406 T HR P20220406T HR P20220406 T1 HRP20220406 T1 HR P20220406T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- enzyme
- antibody
- use according
- human arginase
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 6
- 229940045207 immuno-oncology agent Drugs 0.000 title claims 5
- 239000002584 immunological anticancer agent Substances 0.000 title claims 5
- 239000004475 Arginine Substances 0.000 title claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 3
- 238000000034 method Methods 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 1
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 claims 13
- 102000053089 human ARG1 Human genes 0.000 claims 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 229910017052 cobalt Inorganic materials 0.000 claims 8
- 239000010941 cobalt Substances 0.000 claims 8
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 102000004452 Arginase Human genes 0.000 claims 3
- 108700024123 Arginases Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 101710191958 Amino-acid acetyltransferase Proteins 0.000 claims 1
- 108010006591 Apoenzymes Proteins 0.000 claims 1
- 102000009042 Argininosuccinate Lyase Human genes 0.000 claims 1
- 102000053640 Argininosuccinate synthases Human genes 0.000 claims 1
- 108700024106 Argininosuccinate synthases Proteins 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 claims 1
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 238000003287 bathing Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229910001429 cobalt ion Inorganic materials 0.000 claims 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03001—Arginase (3.5.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (14)
1. Farmaceutski pripravak koji sadrži enzim humane arginaze I koji sadrži kofaktor kobalta i imunoonkološko sredstvo za primjenu u metodi inhibicije rasta tumora kod ispitanika, pri čemu je imunoonkološko sredstvo odabrano iz skupine koju čine anti-PD-1 antitijelo, anti-PD-Ll antitijelo, anti-OX40 antitijelo i anti-OX40L antitijelo.
2. Farmaceutski pripravak za primjenu prema patentnom zahtjevu 1, pri čemu tumor sadrži arginin auksotrofnih tumorskih stanica; pri čemu, po mogućnosti, tumor pokazuje smanjenu ili inhibiranu ekspresiju argininosukcinat sintetaze, ornitin transkarbamilaze, argininosukcinat liaze ili njihove kombinacije.
3. Farmaceutski pripravak za primjenu prema patentnom zahtjevu 1, pri čemu je enzim humane arginaze I stabiliziran povezivanjem s polietilen glikolom, ili konjugacijom sa sintetičkim proteinskim polimerom, Fc fragmentom ili albuminom.
4. Farmaceutski pripravak za primjenu prema bilo kojem od patentnih zahtjeva od 1 do 3, pri čemu je enzim humane arginaze I pegiliran.
5. Farmaceutski pripravak za primjenu prema bilo kojem od patentnih zahtjeva od 1 do 4, pri čemu je ispitanik životinja ili čovjek oboljeli od raka.
6. Farmaceutski pripravak za primjenu prema bilo kojem od patentnih zahtjeva od 1 do 5, pri čemu imunoonkološko sredstvo sadrži pembrolizumab, atezolizumab ili nivolumab.
7. Farmaceutski pripravak za primjenu prema bilo kojem od patentnih zahtjeva od 1 do 6, pri čemu je tumor hepatocelularni karcinom, karcinom bubrežnih stanica, rak dojke, melanom, rak prostate, rak gušterače, rak mokraćnog mjehura, rak debelog crijeva, kolorektalni karcinom, trostruko negativni rak dojke, Hodgkinov limfom, rak želuca, glioblastom, karcinom Merkelovih stanica, rak pluća, rak malih stanica pluća ili rak ne-malih stanica pluća.
8. Farmaceutski pripravak za primjenu prema bilo kojem od patentnih zahtjeva od 1 do 7, pri čemu, u metodi inhibicije rasta tumora kod ispitanika, ili:
se enzim humane arginaze I i anti-PD-1 antitijelo, anti-PDL-1 antitijelo, anti-OX40 antitijelo ili anti-OX40L antitijelo daju istodobno; ili
se enzim humane arginaze I i anti-PD-1 antitijelo, anti-PDL-1 antitijelo, anti-OX40 antitijelo ili anti-OX40L antitijelo daju uzastopno.
9. Farmaceutski pripravak za primjenu prema bilo kojem od patentnih zahtjeva od 1 do 8, pri čemu enzim humane arginaze I pokazuje omjer kcat/KM za hidrolizu arginina između 400 mM-1 s-1 i 4.000 mM-1 s-1 pri pH vrijednosti od 7,4 i temperaturi od 37°C; ili
enzim humane arginaze I sadrži omjer kobalta i arginaze od 2 do 3 µgCo/mg arginaze; ili
enzim humane arginaze I je dobavljiv putem kontakta apoenzima arginaze s kobaltom ili ionom kobalta na temperaturi od 30°C do 55°C u razdoblju od 15 minuta do 60 minuta.
10. Kombinacija za primjenu u liječenju raka kod onkološkog pacijenta, pri čemu kombinacija sadrži farmaceutski pripravak koji sadrži pegilirani enzim humane arginaze I koji sadrži kofaktor kobalta i terapija za modulaciju imunološkog sustava koja sadrži farmaceutski pripravak koji sadrži imunoonkološko sredstvo odabrano između anti-PD-1 antitijela, anti-PD-L1 antitijela, anti-OX40 antitijela ili anti-OX40L antitijela, pri čemu:
farmaceutski pripravak koji sadrži pegilirani enzim humane arginaze I koji sadrži kofaktor kobalta i farmaceutski pripravak koji sadrži imunoonkološko sredstvo daju se istodobno; ili
farmaceutski pripravak koji sadrži enzim humane arginaze I koji sadrži kofaktor kobalta i farmaceutski pripravak koji sadrži imunoonkološko sredstvo daju se uzastopno.
11. Kombinacija za primjenu prema patentnom zahtjevu 10, pri čemu terapeutska količina pegiliranog enzima humane arginaze I sadrži kofaktor kobalta od 0,01 mg/kg do 7,5 mg/kg; ili od 0,05 mg/kg do 5 mg/kg ili od 0,1 mg/kg do 5 mg/kg.
12. Kombinacija za primjenu prema patentnom zahtjevu 10 ili patentnom zahtjevu 11, pri čemu je imunoonkološko sredstvo odabrano između pembrolizumaba, atezolizumaba i nivolumaba.
13. Kombinacija za primjenu prema bilo kojem od patentnih zahtjeva od 10 do 12, pri čemu se onkološki pacijent liječi od hepatocelularnog karcinoma, raka bubrežnih stanica, raka dojke, melanoma, raka prostate, raka gušterače, raka mokraćnog mjehura, raka debelog crijeva, kolorektalnog karcinoma, trostruko negativnog raka dojke, Hodgkinovog limfoma, raka želuca, glioblastoma, karcinoma Merkelovih stanica, raka pluća, raka pluća malih stanica ili raka ne-malih stanica.
14. Kombinacija za primjenu prema bilo kojem od patentnih zahtjeva od 10 do 13, pri čemu se farmaceutski pripravak koji sadrži pegilirani enzim humane arginaze I koji sadrži kofaktor kobalta daje parenteralno ili se daje lokalno, intravenozno, intradermalno, intraarterijski, intraperitonearno, intralezijski, intrakranijalno, intraartikularno, intraprostatički, intrapleuralno, intratrahealno, intraokularno, intranazalno, intravitrealno, intravaginalno, intrarektalno, intramuskularno, supkutano, subkonjunktivalno, intravezikularno, mukozno, intraperikardijalno, intraumbilikalno, oralno,inhalacijom, injekcijom, infuzijom, kontinuiranom infuzijom, lokaliziranom perfuzijom izravnim kupanjem ciljanih stanica putem katetera ili ispiranjem.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662372092P | 2016-08-08 | 2016-08-08 | |
| US201762524286P | 2017-06-23 | 2017-06-23 | |
| EP17840420.8A EP3496743B1 (en) | 2016-08-08 | 2017-09-08 | Compositions and methods for treating cancer with arginine depletion and immuno oncology agents |
| PCT/US2017/050816 WO2018032020A1 (en) | 2016-08-08 | 2017-09-08 | Compositions and methods for treating cancer with arginine depletion and immuno oncology agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220406T1 true HRP20220406T1 (hr) | 2022-05-27 |
Family
ID=61163268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220406TT HRP20220406T1 (hr) | 2016-08-08 | 2017-09-08 | Pripravci i metode za liječenje raka deplecijom arginina i imunoonkološkim sredstvima |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10729752B2 (hr) |
| EP (1) | EP3496743B1 (hr) |
| AU (1) | AU2017310541B2 (hr) |
| BR (1) | BR112019002458A2 (hr) |
| CY (1) | CY1125158T1 (hr) |
| DK (1) | DK3496743T3 (hr) |
| ES (1) | ES2909556T3 (hr) |
| GB (1) | GB2568000A (hr) |
| HR (1) | HRP20220406T1 (hr) |
| HU (1) | HUE057901T2 (hr) |
| IL (1) | IL264535B (hr) |
| LT (1) | LT3496743T (hr) |
| PL (1) | PL3496743T3 (hr) |
| PT (1) | PT3496743T (hr) |
| RS (1) | RS63075B1 (hr) |
| RU (1) | RU2771313C2 (hr) |
| SI (1) | SI3496743T1 (hr) |
| WO (1) | WO2018032020A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019002458A2 (pt) | 2016-08-08 | 2019-05-14 | Aerase, Inc. | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos |
| WO2018167780A1 (en) * | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
| WO2020063668A1 (zh) * | 2018-09-25 | 2020-04-02 | 信达生物制药(苏州)有限公司 | 包含抗ox40抗体的制剂、其制备方法及其用途 |
| GB201818576D0 (en) * | 2018-11-14 | 2018-12-26 | Io Biotech Aps | Arginase 2 polypeptides |
| WO2021041904A1 (en) * | 2019-08-30 | 2021-03-04 | Aeglea Biotherapeutics, Inc. | Methods for production of human recombinant arginase 1 and uses thereof |
| WO2022195629A1 (en) * | 2021-03-18 | 2022-09-22 | National Institute Of Pharmaceutical Education And Research (Niper) | Engineered arginase constructs, method of generation and uses thereof |
| CN118497178A (zh) * | 2023-02-15 | 2024-08-16 | 重庆派金生物科技有限公司 | 精氨酸脱亚胺酶突变体、共价二聚体及其偶联物和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02117383A (ja) | 1988-10-26 | 1990-05-01 | Tosoh Corp | ヒトアルギナーゼの製造方法 |
| US5780286A (en) | 1996-03-14 | 1998-07-14 | Smithkline Beecham Corporation | Arginase II |
| EP1499342A2 (en) | 2002-01-25 | 2005-01-26 | Cancer Treatments International | Therapeutic composition for treatment of cancer by arginine depletion |
| HK1053577A2 (en) | 2002-06-20 | 2003-10-10 | Bio Cancer Treatment Int Ltd | Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| CN1745847A (zh) | 2004-09-08 | 2006-03-15 | 康达医药科技有限公司 | 用精氨酸酶治疗肝炎的药物组合物和方法 |
| JP5097714B2 (ja) | 2005-12-12 | 2012-12-12 | カンジ，インコーポレイテッド | Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター |
| DK2350273T3 (en) | 2008-10-31 | 2016-06-13 | Aerase Inc | Compositions of engineered human arginases and methods for the treatment of cancer |
| JP2012531893A (ja) * | 2009-06-29 | 2012-12-13 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | アルギナーゼ製剤および方法 |
| WO2012061015A2 (en) | 2010-11-03 | 2012-05-10 | Scott & White Healthcare | L-citrulline supplementation during arginine depletion therapy with arginase |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| EP4063503A1 (en) | 2014-02-11 | 2022-09-28 | The Regents of the University of Colorado, a body corporate | Crispr enabled multiplexed genome engineering |
| CA2944903A1 (en) * | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| EP2982758A1 (en) | 2014-08-04 | 2016-02-10 | Centre Hospitalier Universitaire Vaudois (CHUV) | Genome editing for the treatment of huntington's disease |
| HUE043847T2 (hu) | 2014-08-28 | 2019-09-30 | Halozyme Inc | Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia |
| US20160161485A1 (en) * | 2014-11-03 | 2016-06-09 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
| US20180271960A1 (en) * | 2015-09-21 | 2018-09-27 | Bio-Cancer Treatment International Ltd. | Method to treat cancer using arginine delpetor and ornithine decarboxylase (odc) inhibitor |
| US11136597B2 (en) | 2016-02-16 | 2021-10-05 | Yale University | Compositions for enhancing targeted gene editing and methods of use thereof |
| BR112019002458A2 (pt) | 2016-08-08 | 2019-05-14 | Aerase, Inc. | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos |
-
2017
- 2017-09-08 BR BR112019002458-1A patent/BR112019002458A2/pt unknown
- 2017-09-08 PL PL17840420T patent/PL3496743T3/pl unknown
- 2017-09-08 WO PCT/US2017/050816 patent/WO2018032020A1/en unknown
- 2017-09-08 DK DK17840420.8T patent/DK3496743T3/da active
- 2017-09-08 LT LTEPPCT/US2017/050816T patent/LT3496743T/lt unknown
- 2017-09-08 US US15/699,951 patent/US10729752B2/en active Active
- 2017-09-08 EP EP17840420.8A patent/EP3496743B1/en active Active
- 2017-09-08 HR HRP20220406TT patent/HRP20220406T1/hr unknown
- 2017-09-08 ES ES17840420T patent/ES2909556T3/es active Active
- 2017-09-08 HU HUE17840420A patent/HUE057901T2/hu unknown
- 2017-09-08 GB GB1903065.9A patent/GB2568000A/en not_active Withdrawn
- 2017-09-08 AU AU2017310541A patent/AU2017310541B2/en active Active
- 2017-09-08 RU RU2019106501A patent/RU2771313C2/ru active
- 2017-09-08 RS RS20220312A patent/RS63075B1/sr unknown
- 2017-09-08 PT PT178404208T patent/PT3496743T/pt unknown
- 2017-09-08 SI SI201731113T patent/SI3496743T1/sl unknown
-
2019
- 2019-01-29 IL IL264535A patent/IL264535B/en unknown
-
2020
- 2020-08-03 US US16/983,635 patent/US20200360493A1/en not_active Abandoned
-
2022
- 2022-04-08 CY CY20221100267T patent/CY1125158T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019002458A2 (pt) | 2019-05-14 |
| RU2771313C2 (ru) | 2022-04-29 |
| SI3496743T1 (sl) | 2022-08-31 |
| US20180177853A1 (en) | 2018-06-28 |
| DK3496743T3 (da) | 2022-04-04 |
| RS63075B1 (sr) | 2022-04-29 |
| GB201903065D0 (en) | 2019-04-24 |
| WO2018032020A1 (en) | 2018-02-15 |
| HUE057901T2 (hu) | 2022-06-28 |
| PL3496743T3 (pl) | 2022-05-30 |
| US10729752B2 (en) | 2020-08-04 |
| CY1125158T1 (el) | 2024-02-16 |
| EP3496743A4 (en) | 2020-03-18 |
| AU2017310541B2 (en) | 2024-06-13 |
| GB2568000A (en) | 2019-05-01 |
| EP3496743A1 (en) | 2019-06-19 |
| US20200360493A1 (en) | 2020-11-19 |
| PT3496743T (pt) | 2022-03-30 |
| ES2909556T3 (es) | 2022-05-09 |
| RU2019106501A3 (hr) | 2021-01-15 |
| RU2019106501A (ru) | 2020-09-14 |
| EP3496743B1 (en) | 2022-02-09 |
| IL264535B (en) | 2022-01-01 |
| AU2017310541A1 (en) | 2019-03-07 |
| IL264535A (en) | 2019-02-28 |
| LT3496743T (lt) | 2022-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220406T1 (hr) | Pripravci i metode za liječenje raka deplecijom arginina i imunoonkološkim sredstvima | |
| Seidl | Targets for therapy of bladder cancer | |
| El-Sayed et al. | Pharmacokinetics, immunogenicity and anticancer efficiency of Aspergillus flavipes L-methioninase | |
| PH12014501119A1 (en) | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate | |
| RU2018140960A (ru) | Композиции, содержащие комбинированный состав на основе антител к pd-l1 и ctla-4 | |
| JP2017502017A5 (hr) | ||
| MY161861A (en) | Pyrrolo [2,3-] pyridine kinase inhibitors | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| RU2017123972A (ru) | Стабильная водная композиция антитела против фактора роста эндотелия сосудов (VEGF) | |
| US20210130450A1 (en) | Egfl6 specific monoclonal antibodies and methods of their use | |
| O'Donnell et al. | Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6 | |
| EA201500826A1 (ru) | Содержащая альбуминсвязывающую аргининдезиминазу фармацевтическая композиция для таргетной терапии рака | |
| Wang et al. | Enhanced and prolonged antitumor effect of salinomycin-loaded gelatinase-responsive nanoparticles via targeted drug delivery and inhibition of cervical cancer stem cells | |
| EA201691053A1 (ru) | Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии | |
| RU2014145841A (ru) | Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы | |
| AR088509A1 (es) | Combinaciones terapeuticas y metodos para tratar el melanoma | |
| CN104473973A (zh) | 一株戈氏梭菌驯化株的应用 | |
| Xu et al. | Bacteria-mediated tumor immunotherapy via photothermally-programmed PD1 expression | |
| TR201908872T4 (tr) | Üçlü negatif meme kanserini tedavi etmek için ajanlar. | |
| Xu et al. | Construction and characterization of a truncated tissue factor‑coagulation‑based composite system for selective thrombosis in tumor blood vessels | |
| Lee | Osteosarcoma in Korean children and adolescents | |
| Zhong et al. | Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer | |
| Wu et al. | Overexpression of KAI1 induces autophagy and increases MiaPaCa-2 cell survival through the phosphorylation of extracellular signal-regulated kinases | |
| JP2019529526A5 (hr) |